Laboratory measures of adherence and additional laboratory measures in the SPRINT trial
| . | Laboratory measures of hydroxyurea adherence∗ . | Additional laboratory measures∗ . | ||||
|---|---|---|---|---|---|---|
| MCV, fL . | Total Hb, g/dL . | White blood cell count, ×109/L . | ANC per μL . | Platelets, ×103/μL . | HbF (n = 93), % . | |
| Low-dose group (N = 49) | ||||||
| Baseline | 84.0 | 7.9 | 14.4 | 6594 | 469 | 8.2 |
| End point | 88.1 | 8.4 | 13.2 | 6018.7 | 376 | 10.6 |
| Moderate-dose group (N = 50) | ||||||
| Baseline | 82.8 | 8.0 | 13.2 | 5790.7 | 433 | 7.7 |
| End point | 95.8 | 8.8 | 9.4 | 4118.8 | 301.5 | 15.8 |
| P value for end points of low- vs moderate-dose groups† | .01 | .127 | <.001 | <.001 | .003 | .002 |
| . | Laboratory measures of hydroxyurea adherence∗ . | Additional laboratory measures∗ . | ||||
|---|---|---|---|---|---|---|
| MCV, fL . | Total Hb, g/dL . | White blood cell count, ×109/L . | ANC per μL . | Platelets, ×103/μL . | HbF (n = 93), % . | |
| Low-dose group (N = 49) | ||||||
| Baseline | 84.0 | 7.9 | 14.4 | 6594 | 469 | 8.2 |
| End point | 88.1 | 8.4 | 13.2 | 6018.7 | 376 | 10.6 |
| Moderate-dose group (N = 50) | ||||||
| Baseline | 82.8 | 8.0 | 13.2 | 5790.7 | 433 | 7.7 |
| End point | 95.8 | 8.8 | 9.4 | 4118.8 | 301.5 | 15.8 |
| P value for end points of low- vs moderate-dose groups† | .01 | .127 | <.001 | <.001 | .003 | .002 |
Based on the intention-to-treat analysis, participants were allocated to receive fixed low- (∼10 mg/kg per day) or moderate-dose (∼20 mg/kg per day) hydroxyurea and were followed for a median of 1.6 years (IQR, 1.0-2.3). Only those with entry and exit values are included (n = 99).
Median.
Mann-Whitney test.